Indeed, MEK inhibition, a downstream target of RAS, synergises with prednisolone in the treatment of both RAS-mutant and wildtype ALL [153], potentially underpinned by reduced ROS production following RAS inhibition. Here, MAP2K7 is linked to acute lymphoblastic leukemia.